In-Silico Trials: Computational Modelling and Simulation for Medical Product Innovation and Regulatory Clearance Market for Large Organization Size Segment to Account for Largest Share During 2021-2028

According to our latest study on "In-Silico Trials: Computational Modelling and Simulation for Medical Product Innovation and Regulatory Clearance Market Forecast to 2028 - COVID-19 Impact and Global Analysis - by Organization Size, Offering, Application, Clinical Indication, and End-User, the market is projected to reach US$ 6,830.99 million by 2028 from US$ 2,957.65 million in 2021; it is expected to grow at a CAGR of 12.7% from 2021 to 2028. The report highlights the key factors driving the market growth and prominent players with their developments in the in-silico trials: computational modelling and simulation for medical product innovation and regulatory clearance market growth during the forecast period of 2021 to 2028.

The COVID-19 crisis has significantly triggered the adoption of in-silico trials: computational modelling and simulation for medical product innovation and regulatory clearance market and will continue a similar trend in the coming years. The in-silico trial models have been used to predict the outcome of one of the latest suggested approaches to design an effective vaccine based on monoclonal antibody for SARS-CoV-2, which is one of the infectious diseases that had spread globally. Universal Immune System Simulator (UISS) in silico platform is potentially being used as an in silico trial platform to predict the outcome of vaccination strategy against SARS-CoV-2. Such preliminary supportive factors assist in high adoption of in-silico trials: computational modelling and simulation for medical product innovation and regulatory clearance market amid COVID-19 pandemic resulting in positively impact the overall growth of the market during 2021-2028.

Based on organization size, the overall market is bifurcated into small and medium organizations and large organizations. The large organization segment accounted for a larger market share in 2021 and is projected to register a higher CAGR during the forecast period. The high cost and time necessary for developing a new drug or a new medical device are expensive, particularly for small and medium-sized companies. Therefore, it is widely adopted by large organizations where digital simulations can cut up to 50% of the development cost and duration for drugs and medical devices. For example, regulatory agencies are promoting the utilization of modeling and simulation for medical products, reducing the development time, and also providing cut-through technological innovations. This is one of the prominent factors responsible for the segmental growth, ultimately contributing to the overall market growth during the forecast period of 2021 to 2028.

InSilico Trials Technologies; FEops; CADFEM Medical GmbH; Dassault Systemes SE; Virtonomy GmbH; Certara Inc.; Computational Life; Novadiscovery; TwInsight Medical; Ansys, Inc.; Synopsys, Inc.; Sensyne Health plc; Phesi; Tempus; and Cerner Corporation are among the leading companies operating in the global market during the forecast period of 2021 to 2028.

The report segments the in-silico trials: computational modelling and simulation for medical product innovation and regulatory clearance market as follows:

Based on organization size, the global market is bifurcated into small and medium organizations and large organizations. By offering, the market is segmented into products, platform, and services. Based on application, the total market is segmented into product design and discovery, product development, pre-clinical targeting, assessment of drugs and other biomedical products, and others. Based on clinical indication, the in-silico trials: computational modelling and simulation for medical product innovation and regulatory clearance market is segmented into cardiovascular diseases, neurodegenerative diseases, oncology, rare diseases, metabolic disease, immune based diseases, infectious diseases, and others. By end user, the overall market is segmented based on pharmaceutical and biopharmaceutical companies, medical technology companies, contract research organizations, and others. Based on geography, the in-silico trials: computational modelling and simulation is primarily segmented into North America, Europe, Asia Pacific, the Middle East and Africa (MEA), and South and Central America. The market in North America is further segmented into the US, Canada, and Mexico. The European market is segmented into France, Germany, the UK, Spain, Italy, and the Rest of Europe. The market in Asia Pacific is segmented into China, India, Japan, Australia, South Korea, and the Rest of APAC. The market in the MEA is further segmented into Saudi Arabia, the UAE, South Africa, and the Rest of the MEA. The market in South and Central America is segmented into Brazil, Argentina, and the Rest of South and Central America.

Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@premiummarketinsights.com